— Know what they know.
Not Investment Advice

ALIM NASDAQ

Alimera Sciences, Inc.
1W: +0.2% 1M: -0.9% 3M: +81.6% 1Y: +73.7% 3Y: +0.9%
$5.54
Last traded 2024-09-18 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · $301.3M mcap · 13M float · 6.88% daily turnover

Revenue Segmentation

By Product / Service

Revenue by Segment (5-Year Trend)

Income Trends

Revenue
$81M +49.2% ▲
5Y CAGR: +11.4%
Gross Profit
$61M +32.5% ▲
5Y CAGR: +7.7%
Operating Income
-$2M +83.4% ▲
Net Income
-$20M -11.2% ▼
EPS (Diluted)
$-0.79 +69.5% ▲
EBITDA
-$1M +87.5% ▲

Profit Margins

Year-over-Year Growth

View Full Income Statement
Line ItemFY2019FY2020FY2021FY2022FY2023
Revenue$54M$51M$59M$54M$81M
YoY Growth+14.8%-5.8%+16.2%-8.3%+49.2%
Cost of Revenue$7M$7M$7M$8M$20M
Gross Profit$47M$44M$52M$46M$61M
Gross Margin87.7%86.3%88.1%85.3%75.7%
R&D Expenses$11M$10M$14M$16M$17M
SG&A Expenses$39M$32M$36M$39M$46M
Operating Expenses$53M$44M$52M$58M$63M
Operating Income-$5M-$501K-$201K-$12M-$2M
Operating Margin-9.8%-1.0%-0.3%-21.5%-2.4%
Interest Expense$5M$5M$5M$6M$10M
Income Before Tax-$10M-$5M-$4M-$18M-$20M
Tax Expense$216K-$68K$438K$28K$85K
Net Income-$10M-$5M-$4M-$18M-$20M
Net Margin-19.4%-10.5%-7.4%-33.5%-24.9%
EPS (Diluted)$-2.19$-1.04$-0.66$-2.59$-0.79
EBITDA-$3M$3M$4M-$9M-$1M
Shares Outstanding5M5M7M7M26M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms